Video Series

Dr Gordon provides strategies for navigating treatment-associated toxicities in DLBCL management as directed by NCCN Guidelines.

Dr Gerds provides insight regarding the evaluation of dosing and effectiveness in PV treatment.

A medical expert examines first6, second-, and third-line systemic therapies for DLBCL in accordance with NCCN Guidelines.

Experts explore the importance of early detection of metastatic colorectal cancer.

Specialists examine techniques for assessing pathological complete responses and various methods for response measurement in patients with NSCLC.

Experts explore strategies to increase the number of patients benefiting from multidisciplinary team (MDT) collaboration and the factors MDTs consider when deciding between surgical resection and nonsurgical options for early-stage NSCLC.

Specialists address the intricate factors between comorbidities, efficacy, and tolerance, which influence their treatment approaches at the time of diagnosis.

Specialists evaluate their clinical strategies for managing second-line driver-negative and initial PD-L1 negative patients.

Medical experts discuss considerations for ESRD during CKD treatment as well as updated guidelines for treatment of chronic kidney disease.

Jennifer Green, MD, provides considerations for the use of SGLT2 inhibitors in treatment of CKD.

An overview on the current role of caregivers on patient adherence.

An explanation on the importance of cooperation on the side of providers, payers, and pharmacists in treatment of patients.

Medical experts discuss the financial impact of early detection in colorectal cancer.

Ryan Haumschild, PharmD, MS, MBA, drives a conversation regarding the epidemiology of metastatic colorectal cancer (mCRC) in the US.

Key recommendations and recent updates in the latest version of NCCN guidelines for DLBCL are outlined by Dr Gordon.

Leo Gordon, MD, provides an overview of current treatment strategies currently driven by NCCN guidelines.

Dr Gerds navigates frontline treatments for patients diagnosed with PV.

Dr Gerds reviews the process for updating NCCN guidelines surrounding PV treatment.

Experts examine decision-makers in treatment selection and navigate challenges in organizing multidisciplinary team meetings, from institutional to wider practice perspectives.

Specialists discuss adverse reactions to immunotherapy and explore the importance of CTLA-4 inhibitors in mNSCLC treatment.

Professionals deliberate the progression of Immuno-Oncology combinations while also engaging in conversations regarding the issue of immunotherapy resistance.

A panel of experts review what an effective multidisciplinary approach for NSCLC management looks like and subspecialties included in multidisciplinary teams.

The current treatment landscape for CKD patients with preexisting comorbidities is explored.

Dr Nicholas highlights key objectives in developing CKD treatment strategies.

An overview of the importance of specialty pharmacies, coupons, and product samples.

A discussion on advocating for patients to payers over high-cost drugs and generic drugs.

Dr. Gerd examines the clinical choices involved in the management of PV, following the directives of NCCN guidelines.

Dr Gerds explores similarities and differences in symptomatic patients compared to asymptomatic patients with PV.

Experts examine primary and acquired resistance mechanisms in immunotherapy, while promoting realistic treatment strategies.

Experts explore the utilization of next-generation sequencing, including liquid biopsies, in mNSCLC Diagnosis.